Understand the source comparison
GHRP-6 Acetate vs Other Appetite Stimulants: Research Comparison
The following table compares GHRP-6 acetate for appetite stimulation against other peptides and pharmacological agents used in appetite research, highlighting onset time, mechanism, GH response, and practical considerations for protocol design. GHRP-6 Acetate
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares GHRP-6 acetate for appetite stimulation against other peptides and pharmacological agents used in appetite research, highlighting onset time, mechanism, GH response, and practical considerations for protocol design.
- GHRP-6 Acetate
- GHS-R1a agonist (ghrelin mimetic)
- 20–30 min
- Strong (dose-dependent)
- 90–120 min
- High. Dual appetite + GH effect, stable reconstituted solution
- Ghrelin (endogenous)
- GHS-R1a agonist
- 10–20 min
- Moderate
- 60–90 min
- Low. Rapid enzymatic degradation, requires continuous infusion
- GHRP-2
- Very strong
- Moderate. Stronger GH pulse than GHRP-6, appetite effect less pronounced
- MK-677 (Ibutamoren)
- Oral GHS-R1a agonist
- Sustained (12–24 hr)
- 6–12 hr
- High. Oral administration, prolonged effect, but slower onset
- Orexin-A
- Orexin receptor agonist
- 30–45 min
- None
- 2–4 hr
- Moderate. Central appetite effect, no GH interaction, shorter half-life
- Neuropeptide Y (NPY)
- NPY receptor agonist
- 15–30 min (ICV)
- Low. Requires intracerebroventricular administration, not peripherally active
- GHRP-6 acetate for appetite stimulation stands out for its combination of rapid onset, predictable duration, and dual mechanism. Unlike endogenous ghrelin, which has a plasma half-life of less than 30 minutes due to rapid cleavage by acylated plasma esterases, GHRP-6 resists enzymatic degradation and maintains receptor occupancy for 90–120 minutes. This makes it far more practical for controlled feeding studies where timing and reproducibility matter.
- GHRP-2 shares structural similarity with GHRP-6 but produces a more pronounced GH pulse with slightly weaker appetite effects. For research focused purely on feeding behavior without confounding anabolic hormone changes, GHRP-6 is the preferable choice. For studies investigating the relationship between GH elevation and appetite, GHRP-2 offers a higher GH-to-appetite ratio.
- MK-677, an orally active ghrelin mimetic, provides a longer duration of action (12–24 hours) but with slower onset. It's better suited for chronic dosing studies or protocols where daily injections are impractical. However, the prolonged GH elevation with MK-677 can produce IGF-1 accumulation over weeks, which may alter metabolic parameters independent of appetite. A confound absent with acute GHRP-6 dosing.
- Orexin-A stimulates appetite through hypothalamic orexin receptors rather than ghrelin pathways, making it useful for dissecting overlapping versus independent hunger circuits. However, orexin peptides require intracerebroventricular (ICV) administration in most models, limiting practical application compared to the subcutaneous route used with GHRP-6.